文献速递泌尿系结石

枸橼酸钾与噻嗪类利尿剂用于经验性结石预防的倾向匹配分析

Potassium Citrate vs Thiazides for Empiric Stone Prevention: A Propensity-Matched Analysis.
PubMed 文献 · Urology · 2026-09-17

本研究基于TriNetX数据库的回顾性队列,纳入无明确代谢异常的成人泌尿系结石患者,比较经验性起始枸橼酸钾与噻嗪类利尿剂后3年内结石手术风险。经1:1倾向评分匹配后每组16759例,枸橼酸钾组3年手术风险高于噻嗪类组(5.6% vs 3.5%,HR 1.57,95%CI 1.42-1.74,P<.0001)。结论提示在无代谢异常的经验性治疗人群中,噻嗪类可能提供更一致的临床显著复发保护,但需前瞻性验证。

要点

  • 无代谢异常结石患者经验性用枸橼酸钾,3年结石手术风险高于噻嗪类(5.6% vs 3.5%)。
  • 倾向匹配后枸橼酸钾组手术风险增加57%(HR 1.57,95%CI 1.42-1.74,P<.0001)。
  • 排除治疗交叉后关联持续(5.2% vs 3.0%;HR 1.69),各亚组HR 1.22-1.73。

核心结论

  • 在无明确代谢异常的经验性治疗结石患者中,起始枸橼酸钾与3年内结石手术风险高于噻嗪类利尿剂相关。
  • 提示噻嗪类利尿剂可能对临床显著复发提供更一致的保护,但需前瞻性研究确认。

研究设计与样本

  • 回顾性队列研究,使用TriNetX联邦数据库(含超过1亿患者去标识化EHR与索赔数据)。
  • 纳入≥18岁确诊泌尿系结石并在诊断3个月内起始枸橼酸钾或噻嗪类利尿剂的成人。
  • 排除有靶向治疗代谢异常(尿pH≤6、24小时尿钙≥250 mg或24小时尿枸橼酸≤320 mg)、既往结石手术或既往暴露于两药者。
  • 进行1:1倾向评分匹配,匹配后每组16759例。
  • 主要结局为3年内结石手术(体外冲击波碎石、输尿管镜或经皮肾镜取石术)发生率。

主要发现

  • 匹配后3年,枸橼酸钾组结石手术风险高于噻嗪类组(5.6% vs 3.5%)。
  • 绝对风险差2.11%(95%CI 1.66-2.55),HR 1.57(95%CI 1.42-1.74),P<.0001。
  • 排除治疗交叉后关联持续(5.2% vs 3.0%;HR 1.69)。
  • 所有亚组中关联一致(HR 1.22-1.73)。

临床怎么用

  • 对于无明确代谢异常的结石患者,经验性选择噻嗪类利尿剂可能比枸橼酸钾更有利于降低结石手术风险。
  • 临床决策仍需个体化,并等待前瞻性研究进一步确认。

局限性

  • 回顾性队列设计,可能存在未测量混杂。
  • 使用索赔与EHR数据,结局定义依赖编码准确性。
  • 结论需前瞻性研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of stone surgery among patients with nephrolithiasis empirically initiated on potassium citrate vs thiazide diuretics. METHODS: We performed a retrospective cohort study using TriNetX, a federated database containing de-identified EHR and claims data from over 100 million patients. Adults (≥18 years) diagnosed with urolithiasis initiated on potassium citrate or a thiazide diuretic within 3 months of diagnosis were identified. Patients with documented metabolic abnormalities favoring targeted therapy (urine pH ≤6, 24-hour urine calcium ≥250 mg, or 24-hour urine citrate ≤320 mg), prior stone surgery, or prior exposure to either medication were excluded to approximate an empiric treatment cohort. One-to-one propensity score matching was performed. The primary outcome was 3-year incidence of stone surgery, defined as extracorporeal shock wave lithotripsy, ureteroscopy, or percutaneous nephrolithotomy. Sensitivity analyses excluded treatment crossover and stratified by hypertension and stone recurrence status. RESULTS: After matching, 16,759 patients were included in each cohort. At 3 years, patients initiated on potassium citrate had a higher risk of stone surgery than thiazide-treated patients (5.6% vs 3.5%, absolute risk difference 2.11%, 95% CI 1.66-2.55, hazard ratio 1.57, 95% CI 1.42-1.74, P<.0001). This association persisted after excluding treatment crossover (5.2% vs 3.0%; HR 1.69) and across all subgroups (HR 1.22-1.73). CONCLUSION: Among patients without documented metabolic abnormalities empirically treated for nephrolithiasis, potassium citrate initiation was associated with a higher risk of subsequent stone surgery compared to thiazide diuretics. These findings suggest thiazide diuretics may be associated with more consistent protection against clinically significant recurrence, though prospective confirmation is needed.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Tzeng M, Bhambhvani H, Del Pizzo J, et al. Potassium Citrate vs Thiazides for Empiric Stone Prevention: A Propensity-Matched Analysis. Urology. 2026. PMID: 42753980. doi:10.1016/j.urology.2026.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。